Related Experiment Video
Updated: Jul 20, 2026

Study of the Actin Cytoskeleton in Live Endothelial Cells Expressing GFP-Actin
Published on: November 18, 2011
The role of protein kinase C in thromboxane A2-induced pulmonary artery vasoconstriction
Y M Murtha1, B M Allen, J A Orr
1Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.
Abstract:
In order to determine if protein kinase C (PKC) plays a significant role in the stimulant action of thromboxane A2 (TxA2) on pulmonary vascular smooth muscle, TxA(2)-induced contractile responses were measured following inhibition of PKC. Rabbits were sacrificed and segments of the main trunk of the pulmonary artery were removed and placed within a temperature-controlled (37 degrees C) organ bath. Contractile responses that were evoked by a TxA2 mimetic (U46,619, 0.5 microM) decreased by 27 and 35% following treatment with the PKC inhibitors, calphostin C (2 microM) and staurosporine (200 nM), respectively. These results account for the effect of the vehicle, DMSO, which was also found to have a concentration-dependent inhibitory effect on the U46,619-induced contractions. The effects of DMSO alone was subsequently subtracted from the previously measured responses to PKC inhibitors that were dissolved in DMSO to obtain effects attributable to the PKC inhibitor alone. It can therefore be concluded that inhibition of PKC results in partial attenuation of U46,619-induced responses supporting the hypothesis that activation of PKC plays a partial role in TxA2-induced contraction of pulmonary arterial smooth muscle.
More Related Videos
Related Concept Videos
Amplifying Signals via Enzymatic Cascade
MAPK Signaling Cascades
cAMP-dependent Protein Kinase Pathways
Nitric Oxide Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

